My Ultimate Sign-in System Made Me Invincible - Chapter 496 Volunteer Selection Criteria Speculations

Chapter 496 Volunteer Selection Criteria Speculations

It had been more than ten days since Nova Technologies posted the announcement on LucidNet, informing the world that the off-world clinical trial commencement had been pushed forward.

They had promised to post a volunteer selection announcement within twelve days, but nothing had been posted yet.

The silence wasn’t surprising at this point. Nova Technologies operated on their own timeline and had demonstrated that repeatedly. But the waiting produced its own particular kind of tension — not the explosive frustration of the first days after the nanite announcement, but something quieter and more focused. People were paying attention, checking for updates, and filling the silence with speculation.

The ideological arguments between supporters and critics had cooled slightly. Not resolved — nothing had been resolved — but the intensity had dropped from a roar to a sustained hum. Both sides had largely exhausted their strongest points and were now maintaining positions rather than advancing them.

A brief attempt to shift the conversation toward comparing Nova Technologies to pharmaceutical companies had collapsed almost immediately. Both sides had turned on the person who made the post with unusual unity, and the post was deleted within minutes.

It was one of the rare moments where the two camps agreed on something: that particular comparison served no one’s argument well and muddied water that was already murky enough.

What replaced it was more focused. People had turned their attention to the volunteer selection criteria, and the speculation there was running at full volume.

The obvious answers had been covered quickly. Terminal diagnoses. Conditions with no existing treatment options. Genetic diseases present from birth. Spinal injuries. Limb loss. These appeared in every thread as baseline assumptions — conditions so severe and so clearly beyond current medical capability that almost no one disputed them as likely priorities.

But the obvious answers ran out fast, and that’s where the real discussions began.

***

A user posted a thread that gained traction quickly: “Here’s what I think people are underestimating about the selection criteria: Nova Technologies isn’t just running a medical trial. They’re running a demonstration. The conditions they select will be chosen partly for their medical significance and partly for their persuasive impact. They need results that are impossible to dismiss, impossible to attribute to placebo, impossible to replicate through any existing treatment. That means they’ll prioritize conditions where success is visually and statistically undeniable.”

The thread continued: “Think complete spinal cord injuries. Not partial damage — complete severance. The kind where every major medical institution on the planet agrees there is no recovery pathway. If someone with a complete spinal cord injury walks out of Lunar Base Sanctuary, there is no argument. No methodology dispute. No ‘well, maybe they would have recovered anyway.’ The result speaks for itself and cannot be explained away.”

The responses were largely engaged rather than combative.

One user replied: “This makes sense but it also raises an uncomfortable question. If selection is partly about persuasive impact, then people with less visually dramatic conditions — chronic pain, autoimmune disorders, conditions that are debilitating but invisible — might get deprioritized even if their suffering is just as real. A successful nanite treatment for lupus is medically significant but it doesn’t make for the same undeniable visual confirmation as someone walking for the first time in twenty years.”

Another user responded: “That’s a fair concern, but I think you’re applying the wrong framework. Nova Technologies isn’t a pharmaceutical company trying to get FDA approval for a specific drug targeting a specific condition. They’re demonstrating a platform technology. The nanites can theoretically address any biological dysfunction. So they’re not selecting for conditions where the nanites work — they’re selecting for conditions that best demonstrate the range of what the platform can do. Breadth matters as much as impact.”

A separate thread focused on a different angle entirely.

“Everyone is assuming the selection criteria will be purely medical,” a user posted. “But Nova Technologies thinks regionally. Every decision they’ve made has been deliberate — the pricing tiers, the observer framework, the timeline acceleration. None of that was accidental. So why would volunteer selection be different? If a meaningful percentage of volunteers come from regions where the conditions being treated are endemic, the demonstration becomes something else entirely. It stops being just a medical trial and starts being proof that the technology was built for everyone, not just people who already have options.”

The thread developed the argument: “If they select volunteers exclusively from wealthy nations with strong existing healthcare infrastructure, the narrative writes itself — they’re helping people who already have options. But if a meaningful percentage of volunteers come from regions where the conditions being treated are endemic, where existing healthcare simply cannot address them, the demonstration becomes something different entirely. It becomes proof of accessibility intent, not just medical capability.”

A user pushed back: “That introduces a variable that has nothing to do with medicine. You’re suggesting they factor in national origin as a selection criterion, which raises obvious questions about whether that’s appropriate. Medical selection should be based on medical need, not on where someone was born or what narrative their recovery serves.”

Another responded: “But medical need and geographic distribution of medical need are related. Certain conditions are far more prevalent in specific regions because of environmental factors, genetic prevalence, or healthcare access gaps. If Nova Technologies is prioritizing conditions where existing treatment options are inadequate or nonexistent, geographic diversity in the volunteer pool follows naturally from that. It’s not political theater — it’s an accurate reflection of where the unmet medical need actually is.”

A thread that generated sustained engagement came from a user who approached the question from an entirely different direction.

“I haven’t seen anyone talk about age as a selection variable, and I think it’s one of the most significant ones. The nanites can apparently correct genetic anomalies. That means the question of when in a person’s life those anomalies are corrected becomes medically interesting. A genetic condition corrected at forty, after decades of accumulated biological impact from living with it, produces different data than the same condition corrected at eight, before secondary effects have compounded. Both are valuable. But the data they generate is different.”

The thread continued: “This makes pediatric cases medically significant in a specific way that adult cases aren’t. And it also makes them ethically complicated in a specific way that adult cases aren’t. Children can’t consent. Parents consent on their behalf. And the stakes of an experimental trial, even one with high confidence in safety, are different when the subject is a child.”

A user with apparent medical background responded: “This is actually one of the more substantive points in this thread. Pediatric inclusion in clinical trials has its own entire regulatory and ethical framework that exists precisely because the consent problem is real and significant. Nova Technologies won’t be subject to those frameworks in the conventional sense given the off-world jurisdiction, but that doesn’t mean they won’t apply equivalent standards. A company that has gone to the lengths they’ve gone to with observer access and transparency protocols is not going to casually skip pediatric consent frameworks.”

Another user added: “Worth noting that pediatric genetic conditions are also among the most emotionally undeniable demonstration cases. A child born with a condition corrected in a month, who then develops normally — that’s not a story anyone can argue against on any level. Medical, ethical, emotional. It lands completely.”

The arguments continued and everyone has a valid point.

But out of the post, a quieter but widely shared one came from a user who wasn’t speculating about criteria at all.

“I’ve had ALS for three years. I’m not posting this for sympathy. I’m posting it because I’ve been watching this conversation and I want to say something to other people in my position who might be reading it. We don’t know what the criteria will be. We don’t know when the announcement comes. We don’t know if conditions like mine will be included in this phase or a later one. But something is happening. That’s real, regardless of everything else. Whatever Nova Technologies is, whatever you think of their commercial model or their silence or their pricing structure — something is actually happening. For the first time in three years, I’m genuinely uncertain about what the next year looks like. That uncertainty is not nothing.”

The post accumulated hundreds of thousands of likes within hours. The comments were mostly quiet — people responding with the kind of restraint that comes from recognizing that the moment doesn’t need noise added to it.

A few hours later, someone replied to that post with a single line: “The announcement dropped. Go read it.”